Corticosteroid Emflaza Receives FDA Approval As Duchenne Muscular Dystrophy Treatment A new drug approved by the FDA has been shown to delay loss of walking ability for patients diagnosed with Duchenne muscular dystrophy. Emflaza is marketed by Marathon Pharmaceuticals. by Dianne Depra
Health BioMarin To Halt Development Of $680M Duchenne Muscular Dystrophy Drug by Catherine Cabral-Isabedra